SH-DS01 on Fecal Metagenomic Stability

Inclusion Criteria: * Patient must be willing and able to give informed assent/ consent for participation in the study * Patient must be willing and able (in the PI's opinion) to comply with all study requirements. * Patient must be a premenopausal female or male aged 18 and older. * Patient must have a documented history of IBS that is not completely controlled by current IBS drugs. * Patient must have a score of ≥150 on the IBS-SSS at screening. * Patient must have no clinically relevant (in the judgment of the PI) abnormal blood laboratory levels at screening or randomization. * The clinician will assess eligibility as per the Rome IV criteria (Recurrent abdominal pain or discomfort at least 1 day/week in the last 3 months associated with two or more of the following: Improvement with defecation. Onset associated with a change in frequency of stool). Exclusion Critieria: * Patient has clinically significant unstable medical conditions other than IBS. * Patient has had clinically relevant symptoms or a clinically significant illness in the four weeks prior to screening or randomization. * Patient has clinically significant laboratory values (in the PI's opinion). * Patient is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid based medications (including Sativex®) or supplements (including hemp oil/extracts) within one month prior to study entry and is unwilling to abstain for the duration for the study. * Patient has con…